Semaglutide vs. tirzepatide: how to actually decide between them

Let's start with the mechanism, because the mechanism is where the two drugs actually differ — and understanding that difference is what makes the rest of the decision legible.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, binding to GLP-1 receptors in the pancreas, gut, and brain. This drives insulin secretion, slows gastric emptying, reduces appetite, and modulates the brain's reward circuitry around food. It's a well-understood mechanism at this point — semaglutide has been in clinical use since 2017, first for type 2 diabetes and later for weight management, and the data is extensive.

Tirzepatide is a dual agonist. It activates both GLP-1 receptors and GIP receptors — GIP stands for glucose-dependent insulinotropic polypeptide, a second incretin hormone. For a long time, GIP was considered a secondary player in the metabolic story — it had been studied for decades without becoming therapeutically important. Tirzepatide changed that picture considerably. GIP receptors are expressed in fat tissue, the pancreas, the brain, and bone, and activating them alongside GLP-1 appears to produce synergistic effects on appetite, insulin sensitivity, and fat metabolism that GLP-1 alone does not fully replicate. The exact mechanism of synergy is still being worked out in the research literature, but the clinical effects are visible in the trial data.

The headline trial comparison is SURMOUNT-1 (tirzepatide for weight management) versus STEP 1 (semaglutide for weight management). In SURMOUNT-1, participants on the highest tirzepatide dose lost an average of roughly 22% of body weight over 72 weeks. In STEP 1, participants on the highest semaglutide dose lost an average of roughly 15% over 68 weeks. These are not perfectly apples-to-apples comparisons — different populations, different trial designs, different timeframes. The more direct comparison comes from SURPASS-2, a head-to-head trial of tirzepatide versus semaglutide specifically in people with type 2 diabetes, which found significantly greater weight loss and A1C reduction in the tirzepatide arm across all doses tested. In that trial, even the lowest tirzepatide dose (5 mg) outperformed the highest semaglutide dose (1 mg) on weight-related outcomes.

So if the question is purely "which produces more weight loss in clinical trials," tirzepatide has the advantage in current evidence. But that's not quite the right question, and the right question is more textured.

For someone with 30 or more pounds to lose who is metabolically disrupted — elevated fasting insulin, pre-diabetes or type 2 diabetes, significant insulin resistance, or a strong family history of metabolic disease — the data favors tirzepatide. The dual mechanism appears to address insulin sensitivity more aggressively than semaglutide alone, and when the metabolic disruption is significant, that extra mechanism may matter. The GIP component seems to particularly affect how the body handles fat storage and how fat tissue responds to the caloric deficit, which could explain part of why the weight loss magnitude difference is as large as it is.

For someone with 10 to 15 pounds to lose whose primary metabolic concerns are moderate — fasting glucose that's crept up, some food noise, weight that accumulates despite reasonable habits — semaglutide is often sufficient and has two meaningful practical advantages: cost and a longer track record. Compounded semaglutide is generally less expensive than compounded tirzepatide, and when the metabolic burden is lighter, the second mechanism of tirzepatide may produce marginal additional benefit that doesn't justify the cost difference for everyone. Semaglutide has also been studied in more populations over a longer period, which means the side effect profile and long-term behavior are better characterized.

Side effects deserve an honest paragraph, because this is where a lot of people make their decision and where there's genuine nuance. Both drugs cause GI side effects — nausea, sometimes vomiting, constipation, loose stools depending on the person. These are most common in the first weeks of titration and typically improve. The comparison between the two is not as simple as "tirzepatide has fewer side effects." What the clinical reports and some trial data suggest is that the *nausea profile per amount of weight lost* may be more favorable with tirzepatide — meaning you may lose more weight with comparable or lower GI burden — but this is not a universal experience, and some people find semaglutide's side effect profile more manageable for their specific physiology. The only way to know which one agrees with your system is to try one.

One clinically relevant difference: semaglutide has a longer half-life and may produce a steadier week-long exposure, while tirzepatide's dual mechanism means the pharmacodynamics are more complex. Some providers find that semaglutide is more predictable in terms of how patients respond to titration, and that tirzepatide's effects can be more variable early in treatment. This is clinical pattern recognition more than definitive data, but it's worth knowing.

The insurance and cost picture is complicated and changing. Branded semaglutide (Ozempic for diabetes, Wegovy for weight management) and branded tirzepatide (Mounjaro for diabetes, Zepbound for weight management) have very different insurance coverage stories depending on your plan and your diagnosis. Compounded versions of both are available through prescribing providers, and the cost difference between compounded semaglutide and compounded tirzepatide varies by provider and dose. Before letting cost make the decision for you, it's worth getting specific numbers from your prescribing provider rather than assuming — the landscape shifts and the actual difference may be smaller than you expect, or larger.

There are a few other factors worth naming before any decision is made. Prior treatment history matters: if you tried semaglutide and had limited response at full therapeutic dose, tirzepatide is the more logical next step because the added GIP mechanism may produce different results. Cardiovascular history matters: semaglutide has demonstrated cardiovascular benefit in the SELECT trial (reduction in major cardiovascular events in people with obesity and established cardiovascular disease), and while tirzepatide has cardiovascular trials underway, the evidence at this level of specificity currently favors semaglutide for people where cardiovascular risk reduction is a primary goal alongside weight. Kidney and liver disease change the pharmacokinetic picture for both drugs, and those conversations belong with your prescribing provider directly.

The question of which peptide to use is not actually a question of which one is "better" in the abstract. It's a question of what your metabolic situation calls for, what you've already tried, what your body can tolerate, and what outcomes you're primarily optimizing for. For someone with significant metabolic disease and substantial weight to lose, the trial evidence points toward tirzepatide. For someone with a lighter metabolic burden or cost constraints or a preference for the drug with a longer track record, semaglutide remains a well-supported option. Both are GLP-1 receptor agonists studied for weight management and metabolic health. The difference between them is mechanism depth and magnitude — tirzepatide is doing more things at once, and for some people that matters a great deal, and for others the single-mechanism approach is entirely sufficient. What this means practically is that the decision is worth making carefully, with someone who knows your specific numbers and history, rather than on the basis of which trial headline was more impressive.